March 25, 2020 / 9:50 PM / in 15 days

BRIEF-Revive Therapeutics Retains Pharm-Olam To Advance Clinical Study For Bucillamine In Treatment Of Infectious Diseases, Including Covid-19

March 25 (Reuters) - Revive Therapeutics Ltd:

* REVIVE THERAPEUTICS - RETAINED PHARM-OLAM, LLC TO ADVANCE CLINICAL STUDY FOR BUCILLAMINE IN TREATMENT OF INFECTIOUS DISEASES, INCLUDING COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below